Tags : Soft Tissue Sarcoma

Taiwan Liposome’s TLC178 Receives EMA’s ODD for Soft Tissue Sarcoma

Vartika Singh January 23, 2019

Shots: The ODD follows P-I/II study assessing TLC178 in patients with advanced malignancies in adults and has resulted in no dose-limiting toxicity till date The EMA’s Orphan Drug Designation (ODD) […]readmore

Biotech

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Vartika Singh January 22, 2019

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS The study […]readmore

Tags : Soft Tissue Sarcoma

Taiwan Liposome’s TLC178 Receives EMA’s ODD for Soft Tissue Sarcoma

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Soft Tissue Sarcoma

Taiwan Liposome’s TLC178 Receives EMA’s ODD for Soft Tissue Sarcoma

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company